ZL-6201

N/A

Report date: 2026/05/13 20:02:10
First In Class

Base Information

Drug NameZL-6201
Drug Alias NameZL-6201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-LRRC15
TargetsLeucine-rich repeat-containing protein 15
Therapy Area/IndicationsSolid tumoursSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZai Lab Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZai Lab (Us) LlcZai Lab LtdZai Lab (Shanghai) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A